5-Aminolaevulinic acid-based photodynamic therapy for actinic keratosis in Chinese patients: A prospective multicenter study  

作　　者：Menglong Ran Wenyu Wu Yang Tang Liang Zhang Miaojian Wan Siliang Xue Jianglin Zhang Hang Li 

机构地区：[1]Department of Dermatology and Venerology,Peking University First Hospital,National Clinical Research Center for Skin and Immune Diseases,Beijing Key Laboratory of Molecular Diagnosis on Dermatoses,Beijing 100034,China [2]Department of Dermatology,Huashan Hospital,Fudan University,Shanghai 200040,China [3]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650032,China [4]Department of Dermatology,Wuhan No.1 Hospital,Wuhan,Hubei 430022,China [5]Department of Dermatology,The 3rd Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510630,China [6]Department of Dermatology,Sichuan University West China Hospital,Chengdu,Sichuan 610044,China [7]Shenzhen People’s Hospital(The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,Guangdong 518020,China

出　　处：《Chinese Medical Journal》2024年第12期1510-1512,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Actinic keratosis(AK)is a precancerous skin condition caused by chronic exposure to ultraviolet radiation.It mainly occurs on sun-exposed areas like the head and face,leading to cosmetic concerns and an increased risk of progressing to primary squamous cell carcinoma(with a 0.60%risk at 1 year and 2.57%risk at 4 years).[1]Photodynamic therapy(PDT)is a targeted,non-invasive therapy that has been approved in Europe for the treatment of AK,squamous cell carcinoma in situ,and basal cell carcinomas.5-Aminolaevulinic acid(ALA)-based PDT,which utilizes the photosensitizer ALA,has shown high cure rates,low recurrence rates,and favorable cosmetic outcomes as arst-line treatment for AK.[1]However,due to variations in skin color,ethnicity,and lifestyle habits,the incidence of AK is lower among Asians compared to Caucasians.[1]There are limited clinical studies on PDT for AK in Asia—particularly lacking large-scale multicenter trials.This knowledge gap hinders the establishment of treatment standards specically tailored for Asian patients with AK undergoing PDT.Nevertheless,as the aging population increases in Asia,the incidence of AK demand for medical intervention among Asians is also rising accordingly.We conducted this multicenter study aiming to comprehensively investigate the efcacy and safety of ALA-PDT in Chinese patients with AK.

关 键 词：PATIENTS TREATMENT utilize 

分 类 号：R758.1[医药卫生—皮肤病学与性病学]